americanpharmaceuticalreviewMarch 01, 2021
Tag: HARMONY , Akero , NASH , Efruxifermin
Akero Therapeutics has screened the first patients for its Phase 2b HARMONY study evaluating efruxifermin (EFX), the company's lead product candidate for the treatment of NASH.
"The initiation of our Phase 2b HARMONY study is an important milestone that builds on strong data from our Phase 2a BALANCED study," said Andrew Cheng, M.D., Ph.D., President and CEO of Akero Therapeutics. "We previously showed that EFX has the potential to reverse fibrosis among treatment responders after just 16 weeks of treatment. The HARMONY study will evaluate fibrosis improvement among all study participants after 24 weeks of treatment. We continue to believe that EFX has the potential to be a foundational NASH monotherapy by directly reversing fibrosis and resolving the underlying disease drivers that lead to fibrosis, and by improving risk factors for cardiovascular disease, which remains the leading cause of mortality for NASH patients."
The Phase 2b HARMONY study is a multicenter, randomized, double-blind, placebo-controlled, clinical trial in biopsy-confirmed NASH patients with fibrosis stage 2 or 3. Patients will be randomized to receive once-weekly subcutaneous dosing of 28 or 50mg EFX or placebo. The primary endpoint for the trial is fibrosis regression at 24 weeks. Patients will continue to receive EFX or placebo during a long-term follow-up period to provide additional safety data.
The company expects to dose patients beginning early in the second quarter of this year and to report topline results in the second half of 2022.
Non-alcoholic steatohepatitis (NASH) is a serious, life-threatening disease that has rapidly emerged as a leading cause of liver failure in the world and is the leading indication for liver transplant among women. An estimated 17.3 million Americans had NASH in 2016, a number that is expected to increase to 27.0 million by 2030. NASH is a severe form of nonalcoholic fatty liver disease (NAFLD) characterized by hepatocyte injury, liver inflammation, and fibrosis that can progress to scarring (cirrhosis), liver failure, cancer and death. There are currently no approved therapies for the disease.
Efruxifermin (EFX) is an Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. Previous clinical trials show that EFX has the potential to reverse fibrosis, resolve NASH, reduce liver fat, improve glycemic control, improve lipoprotein profile, and reduce body weight. EFX offers convenient once-weekly subcutaneous dosing.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: